Clinical Trial Update: Effects of Psilocybin in Post-Treatment Lyme Disease [Phase 1]

View source ↗

Summary

A Phase 1 study at Johns Hopkins evaluating psilocybin for post-treatment Lyme disease syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lyme Disease
• Post-treatment Lyme Disease Syndrome

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Johns Hopkins University | Conditions: Post-Treatment Lyme Disease, Chronic Lyme Disease | Phase 1 | Status: COMPLETED